Chikungunya vaccine development, challenges, and pathway toward public health impact
Vaccine·
- DOI
- 10.1016/j.vaccine.2024.126483
- PMID
- 39467413
- PMCID
- —
- OpenAlex
- W4403883422
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The article is relevant to decisions about chikungunya vaccine introduction, financing, manufacturing scale-up, equitable distribution, and demand generation in at-risk populations. It identifies evidence on disease burden and vaccination impact as important inputs for such decisions.
Structured evidence summary
Research question
The article examines the chikungunya vaccine development pipeline and the challenges affecting vaccine licensure, access, uptake, and introduction in populations at risk.
Study design
This is a peer-reviewed journal article presenting a descriptive assessment of chikungunya vaccine candidates and the policy, regulatory, financing, and access issues relevant to their use. The supplied abstract does not specify a systematic review method or primary data collection.
Population and setting
The discussion concerns populations at risk in chikungunya endemic and epidemic settings across multiple geographic regions. The abstract reports outbreaks since 2004 in more than 114 countries across Asia, Africa, the Americas, Europe, and Oceania.
Main findings
The abstract reports that Ixchiq was licensed by the US FDA, EMA, and Health Canada during 2023 and 2024, and identifies five additional vaccine candidates in development. It emphasizes the need for disease-burden, public-health, economic, regulatory, financing, manufacturing, and access evidence to support vaccine introduction, and proposes a global consortium to address these issues.
Public-health relevance
The article is relevant to decisions about chikungunya vaccine introduction, financing, manufacturing scale-up, equitable distribution, and demand generation in at-risk populations. It identifies evidence on disease burden and vaccination impact as important inputs for such decisions.
Important limitations
No explicit study limitations are provided in the supplied abstract. This summary is limited to the supplied single-article abstract and metadata; the original paper is required for decision-grade interpretation of methods, evidence selection, and the strength of the article's assessments.
GIDS interpretation
The article is discoverable as context on chikungunya vaccine development, licensure, and implementation challenges. The supplied evidence does not establish or validate a current surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 13 auditable classifier relationships to diseases, places, topics, and study design.